RxDoctor Payments Data

Cecile Pasion-Bregman, MD

Psychiatry · Stockbridge, GANPI 1396832002

Payments from drug & device makers

$659in general payments, 2019–2025

Across 26 payments — averaging $25.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$126
  • AbbVie$118
  • Sanofi-aventis U.S. LLC$117
  • Sunovion Pharmaceuticals Inc.$116
  • Takeda Pharmaceuticals U.S.A., Inc.$67
  • Shire North American Group Inc$44
  • plus $70 from 4 others

What the payments were for

  • Food & beverage$659100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$659 in reported general payments places this provider in the 55th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$20,191
Medicare patients
32
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide22$14,749
Desvenlafaxine Succinate ErDesvenlafaxine Succinate24$2,159
Ziprasidone Hcl35$1,886
Fluoxetine Hcl60$1,387
Duloxetine Hcl68$1,373
Venlafaxine Hcl ErVenlafaxine Hcl39$1,348
Buspirone Hcl105$1,323
Trazodone Hcl84$1,227
Bupropion XlBupropion Hcl64$974
Clonazepam114$897
Lamotrigine78$856
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine18$736
Quetiapine Fumarate14$720
Clozapine12$671
Alprazolam145$494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$67$14,74922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Stockbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →